OMITTED

What the news leaves out.

← Omitted front page

GLP-1 Drug Users Face Mental Health Risks After Stopping

13 sources · updated 2026-11-12
U.S. Food and Drug Administration
Photo: The U.S. Food and Drug Administration / Wikimedia Commons · Public domain · file · licence
Left 46% Center 31% Right 23%
6 left · 4 center · 3 right

What happened

On Monday, the U.S. Food and Drug Administration (FDA) announced it will require new safety warnings on all GLP-1 receptor agonist drugs, including popular brands like Ozempic, Wegovy, Mounjaro and Zepbound. The labels must now disclose a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare "eye stroke" in which reduced blood flow to the optic nerve can cause sudden, often irreversible vision loss. The decision follows an FDA review of 126 clinical trials involving more than 134,000 patients, post‑marketing adverse event reports, and published studies, including a 2024 JAMA Ophthalmology paper that first raised concerns about semaglutide and NAION. Across trials, the FDA estimated about 6.4 NAION cases per 100,000 patient‑years among GLP-1 users versus about 3.8 among patients on placebo or other glucose‑lowering drugs, but said the biological mechanism is unclear and a causal relationship has not been definitively established. NAION is rare and already associated with conditions common in GLP-1 users, such as type 2 diabetes, hypertension and sleep apnea, yet the FDA concluded there is a "potential increased risk" warranting a class‑wide label change.
Sourcing check · Mostly on the record · 13 articles

10 of 11 articles cite a named source for the story. It was on the record from the first report. Novo Nordisk denied part of it on the record.

What these terms mean and how they're counted
On the record · names a source 10 of 11
On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: FDA, Dr. Frank Dumont, Eli Lilly, Joseph Rizzo and Food and Drug Administration
Primary evidence · cites a document or data 5 of 11
Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: regulatory filing, study, regulatory decision, FDA announcement
Credits another outlet 0 of 11
The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
Unnamed sources 0 of 11
The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
On-record denial 1
A named person or institution says the claim, or part of it, is not true. It is on the record — someone signed their name to it — but it is not confirmation, so it never counts toward On the record. Criticizing or dissenting from a decision is not a denial. The count is how many people or institutions deny it; each is listed with the first article that carried the denial. Here: Novo Nordisk (CBS News, Nov 10, 00:01 UTC)
How it developed
When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Nov 9, 18:14 UTC by NBC News, naming its source. First document in the first report, from NBC News (regulatory filing).
Not counted 2
Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
Omitted — what each side leaves out

Unpacked

The biggest gap is that right-leaning coverage gives readers a simple headcount of how many trial participants were affected, while left-leaning coverage does not. Fox Business says that 10 trial participants developed NAION and that they were part of a much larger GLP-1 group, which makes the rarity more intuitively graspable. Left-leaning outlets describe higher incidence among GLP-1 users than controls and talk about rare events per large populations, but never translate that into how many actual people in the trials lost vision, which can leave the risk feeling more abstract and potentially larger. A secondary pattern is in word choice. Left-leaning coverage uses starker phrasing, with the Guardian warning of "sudden and permanent blindness" from the condition. Right-leaning coverage on Fox Business calls it a "small risk" and quickly adds that it could lead to permanent vision loss, pairing the warning with reassurance about how infrequently it appears. None of the coverage explains how regulators numerically weighed this tiny but serious hazard against the well-documented benefits of GLP-1 drugs, so what threshold of harm would be high enough to change how these medicines are prescribed?
Bottom line

Fox Business spells out that only 10 of roughly 78,000 GLP-1 users in key trials developed the vision-loss condition, while left-leaning outlets focus on the FDA’s new warning and relative risk but never give that simple case count, so readers on each side walk away with a very different gut sense of how big the danger really is.

The receipts — 4 facts one side's coverage lacks
  • Research cited by Fox Business reports that about 43% of patients with significant NAION-related vision impairment experience some spontaneous improvement, though defects remain. numberin foxbusiness · absent from left-leaning coverage
  • The Guardian reports an Access to Medicine Foundation warning that the pharmaceutical focus on GLP-1 weight-loss drugs risks putting global insulin supply at risk. contextin guardian · absent from right-leaning coverage
  • NBC News notes a 2024 JAMA Ophthalmology study in which diabetes patients prescribed semaglutide were four times as likely to develop NAION as those not prescribed the drug. numberin nbcnews · absent from right-leaning coverage
  • The Guardian cites NAION’s general incidence as between 2.3 and 10.2 cases per 100,000 people over age 50 each year. numberin guardian · absent from right-leaning coverage
The Left View
Left-leaning coverage highlights the seriousness of the condition, repeatedly describing NAION as a rare but potentially "sudden" cause of permanent blindness with no known treatment to restore vision. Outlets like NBC News and the Guardian stress that the FDA found NAION cases across all currently marketed GLP-1 drugs and that it is a leading cause of acute optic nerve injury in people over 50, situating the warning within a broader pattern of safety cautions on these medications, including pancreatitis, gallbladder problems, kidney injury and possible thyroid tumors. They emphasize the FDA’s quantitative finding of higher NAION incidence among GLP-1 users than among those on placebo or other diabetes drugs, referencing prior research that showed increased risk, and note that regulators acted despite not yet understanding the mechanism. The Guardian further frames the story within ethical and access debates by pointing out that some people pursue GLP-1s for cosmetic weight loss and by citing a nonprofit warning that intense focus on GLP-1 weight-loss drugs could strain global insulin supply. Drugmakers’ responses are presented as cautious and defensive: Novo Nordisk is quoted as saying the data do not show a cause‑and‑effect relationship but that patient safety remains a top priority, while Eli Lilly is described as reviewing the FDA’s update.
The Right View
Right-leaning coverage characterizes the new label requirement as a response to a very small but serious risk, foregrounding how rare NAION appears in the data. Fox Business notes that only 10 patients taking GLP-1s in roughly 78,000 trial participants developed the condition, which it calculates as about 0.01%, and reports an FDA estimate that GLP-1 users had a roughly 68% higher rate than comparison groups while stressing that this does not prove causation. It underscores the FDA’s own caveats: overlap between NAION risk factors (such as diabetes, high blood pressure and sleep apnea) and the typical GLP-1 user makes it hard to know whether the drugs themselves are responsible, and the underlying cause of NAION is not well understood. The tone balances warning and reassurance by describing NAION as potentially permanent but also mentioning research that around 43% of patients with significant vision impairment see some spontaneous improvement, even though visual field defects usually persist. Fox Business also nods to individual stories of alleged GLP-1‑related blindness and to other safety discussions around these drugs, but keeps the main focus on maintaining perspective about the rarity of the side effect while informing patients of the new label change.
Our Take (balanced)
From the left, the strongest argument is that even an extremely rare risk of sudden, largely irreversible vision loss justifies a clear, class‑wide warning, especially as GLP-1 drugs expand from treating high‑risk diabetes patients to broader weight‑loss use; they point to the FDA’s meta‑analysis, the elevated incidence rate versus placebo or alternative drugs, and the lack of any proven treatment for NAION. From the right, the most compelling argument is that the absolute risk signal is tiny and heavily confounded by the underlying diseases GLP-1s are meant to treat, so the new warning should be understood in proportion to the large, documented benefits of these medications; they emphasize that only 10 cases appeared among tens of thousands of GLP-1 users in trials and that the FDA itself says causality is not established. The central unresolved tension is how regulators, doctors and patients should interpret and act on a very low‑frequency but high‑severity safety signal—one that may be partly driven by pre‑existing risk factors—without either understating a potentially devastating harm or overstating it in a way that deters beneficial treatment.

13 sources

More stories

The week's bottom lines, in your inbox

One email a week: the five stories that mattered and what they actually mean. Free.